AS (alternative splicing) is a fundamental process by which a gene can generate multiple distinct mRNA transcripts to increase protein diversity. Defects in AS influence the occurrence and development of many diseases, including cancers, and are frequently found to participate in various aspects of cancer biology, such as promoting invasion, metastasis, apoptosis resistance and drug resistance. NcRNAs (noncoding RNAs) are an abundant class of RNAs that do not encode proteins. NcRNAs include miRNAs (microRNAs), lncRNAs (long noncoding RNAs), circRNAs (circular RNAs) and snRNAs (small nuclear RNAs) and have been proven to act as regulatory molecules that mediate cancer processes through AS. NcRNAs can directly or indirectly influence a plethora of molecular targets to regulate cis-acting elements, trans-acting factors, or pre-mRNA transcription at multiple levels, affecting the AS process and generating alternatively spliced isoforms. Consequently, ncRNA-mediated AS outcomes affect multiple cellular signaling pathways that promote or suppress cancer progression.
Featured Article: Noncoding RNAs regulate alternative splicing in Cancer
Aims and scope
Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.
Please click here to read more.
Editor-in-Chief
Mauro Castelli, Regina Elena National Cancer Institute, Italy
If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to:
Articles
-
-
HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway
-
Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer
-
Integrated multi-dimensional analysis highlights DHCR7 mutations involving in cholesterol biosynthesis and contributing therapy of gastric cancer
-
Cancer-educated mammary adipose tissue-derived stromal/stem cells in obesity and breast cancer: spatial regulation and function
-
Apoptosis in cancer: from pathogenesis to treatment
-
Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway
-
Effects of short-term fasting on cancer treatment
-
Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007
-
High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
Call for papers: Organoids as clinically relevant models to tailor precision medicine in cancer treatment
Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:
Organoids as clinically relevant models to tailor precision medicine in cancer treatment.
The 2023 Special Issue will accept Research Articles and Reviews regarding the latest highlights on this topic. Submit here.
- Submission opens: 1st January 2023
- Submission deadline: 31st December 2023
Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.
Call for papers: Long non-coding and circular RNAs in the landscape of cancer progression and metastasis
Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:
The role of long non-coding and circular RNAs as potential cancer biomarkers.
The 2022 Special Issue will accept Research Articles and Reviews regarding the latest highlights on this topic. Submit here.
- Submission opens: 1st January 2022
- Submission deadline: 31st March 2023
Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.
Follow JECCR on Social Media
Recognising Editorial Excellence
Journal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.
Reviewer Acknowledgement and New Recruitment
The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to editorialjeccr@gmail.com
Archival content
Journal of Experimental & Clinical Cancer Research has been publishing since 1982. Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print. For enquiries about previous content, please contact us on:
-
-
Owned by the Association for International Promotion & Study in Tumors (APSIT)
-
Official journal of the Regina Elena National Cancer Institute, Scientific Director Gennaro Ciliberto, Rome, Italy
-
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
Annual Journal Metrics
-
Citation Impact
12.658 - 2-year Impact Factor (2021)
11.663 - 5-year Impact Factor (2021)
2.045 - Source Normalized Impact per Paper (SNIP)
2.350 - SCImago Journal Rank (SJR)Speed
5 days to first decision for all manuscripts (Median)
29 days to first decision for reviewed manuscripts only (Median)Usage
2,059,766 Downloads (2021)
1498 Altmetric mentions (2021)